| DGX |
Report |
Organic Req. Volume Growth (Q2 2026) |
BEAT |
pred ~8.5% vs. cons 7.8% |
MEDIUM |
| DGX |
Report |
Revenue per Requisition (Q2 2026) |
IN-LINE |
pred ~$44.20 vs. cons $44.36 |
MEDIUM |
| DGX |
Report |
Adj. Diluted EPS (Q2 2026) |
BEAT |
pred ~$2.87 vs. cons $2.836 |
MEDIUM |
| DGX |
Guide |
FY Revenue (FY 2026) |
BETTER |
guide ~$11.94B midpoint vs. cons $11.850B |
MEDIUM |
| DGX |
Guide |
FY Adj. EPS (FY 2026) |
BETTER |
guide ~$10.85 midpoint vs. cons $10.766 |
MEDIUM |
| DGX |
Guide |
ACA impact commentary (FY 2026) |
UNCHANGED |
Confirm 30bp assumption, no deterioration |
HIGH |
| DGX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.5% |
— |
MEDIUM |
| DGX |
Return |
5-day cumulative residual |
+3.0% (FADE) |
FADE — initial pop partially given back as modest FY raise drives small estimate revisions; no squeeze amplifier; stock stabilizes above day-0 open |
MEDIUM |